Drugging Wnt signalling in cancer

Authors

  • Paul Polakis

    Corresponding author
    1. Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA
    • Corresponding author. Department of Molecular Oncology, Genentech Inc., 1 DNA Way, MS#42, South San Francisco, CA 94080, USA. Tel.:+1 650 225 5327; Fax:+1 650 225 6127; E-mail: ppolakis@gene.com

    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Drugging Wnt signalling in cancer Volume 31, Issue 15, 3375, Article first published online: 1 August 2012

Abstract

Aberrant regulation of the Wnt signalling pathway has emerged as a prevalent theme in cancer biology. This chapter summarizes the research that provides a proof of concept for inhibiting Wnt signalling in cancer, the potential means by which this could be achieved, and some recent advances towards this goal. A brief discussion of molecular diagnostics and possible safety concerns is also provided.

Ancillary